Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

Next Previous
Trial Profile

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reproxalap (Primary) ; Corticosteroids; Prednisolone acetate
  • Indications Anterior uveitis
  • Focus Therapeutic Use
  • Sponsors Aldeyra Therapeutics

Most Recent Events

  • 05 Nov 2020 According to an Aldeyra Therapeutics media release, the peer-reviewed Journal of Ocular Pharmacology and Therapeutics published the positive results of a randomized, corticosteroid-controlled Phase 2 clinical trial of reproxalap in patients with noninfectious anterior uveitis
  • 25 Oct 2017 According to an Aldeyra Therapeutics media release, data from this trial will presented at the American Uveitis Society Fall Meeting held in conjunction with the American Academy of Ophthalmology 2017 Annual Meeting.
  • 17 May 2017 According to an Aldeyra Therapeutics media release, data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top